Navigation Links
InspireMD Postpones $40 Million Registered
Date:11/16/2012

tified and consequently, actual results may differ materially from those expressed or implied by such forward-looking statements. Such risks and uncertainties include, without limitation, risks and uncertainties associated with (i) market acceptance of our existing and new products, (ii) negative clinical trial results or lengthy product delays in key markets, (iii) an inability to secure regulatory approvals for the sale of our products, (iv) intense competition in the medical device industry from much larger, multi-national companies, (v) product liability claims, (vi) our limited manufacturing capabilities and reliance on subcontractors for assistance, (vii) insufficient or inadequate reimbursement by governmental and other third party payers for our products, (viii) our efforts to successfully obtain and maintain intellectual property protection covering our products, which may not be successful, (ix) legislative or regulatory reform of the healthcare system in both the U.S. and foreign jurisdictions, (x) our reliance on single suppliers for certain product components, (xi) the fact that we will need to raise additional capital to meet our business requirements in the future and that such capital raising may be costly, dilutive or difficult to obtain and (xii) the fact that we conduct business in multiple foreign jurisdictions, exposing us to foreign currency exchange rate fluctuations, logistical and communications challenges, burdens and costs of compliance with foreign laws and political and economic instability in each jurisdiction. More detailed information about the Company and the risk factors that may affect the realization of forward-looking statements is set forth in the Company's filings with the Securities and Exchange Commission (SEC), including the Company's Transition Report on From 10-K/T and its Quarterly Reports on Form 10-Q.  Investors and security holders are urged to read these documents free of charge on the SEC's web site at
SOURCE InspireMD, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. InspireMD Elects Sol J. Barer, Ph.D. Chairman of the Board of Directors
2. InspireMD Appoints Dr. James Barry to Its Board of Directors
3. InspireMD to Present at JMP Securities Healthcare Conferenceon July 12th in New York
4. InspireMD to Present at JMP Securities Healthcare Conference on July 12th in New York
5. InspireMD Reports 2012 Fiscal Year Results
6. Avaxia Biologics, Inc. Raises $2.2 Million in First Closing of Series A Financing to Advance Oral Antibodies for Inflammatory Bowel Disease
7. Kansas Bioscience Authority Announces FY11 Outcomes of $207 Million
8. MarketsandMarkets: Global Prostate Cancer Therapeutics Market worth $6,457 Million by 2020
9. Biocartis Completes EUR 71 Million (USD 100 Million) Series C Fund Raising
10. Radius Closes $27.65 Million Second Tranche of Previously Announced Financing
11. BioPower Systems Awarded $5 Million from Victorian Government
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/30/2015)... Nitto Avecia, a leading biotechnology manufacturer and ... production capability to serve biotechnology pharmaceutical clients. A ... continues to drive Nitto Avecia to enhance synthesis ... , In Fall 2014, Nitto Avecia first ... its Milford, MA facility, which is recognized as ...
(Date:4/30/2015)... 30, 2015  Pfenex Inc. (NYSE MKT: PFNX) ... of biosimilar therapeutics including high value and difficult ... its previously announced underwritten public offering of 6,750,000 ... offering price of $15.50 per share. This includes ... their option to purchase up to 750,000 additional ...
(Date:4/30/2015)... FRANCE (PRWEB) April 30, 2015 ... and at http://www.lespausa.com , Phytomer’s DOUCEUR ... sensitive and reactive skin while battling the weakening ... This restorative cream is formulated with star ingredient ... via biotechnology in a complex of soothing minerals ...
(Date:4/29/2015)... 29, 2015 SPIE DSS, ... on the East Coast, reaffirmed its value last week ... developers, and industry suppliers to meet and advance the ... applications. , The event included 55 conferences in two ... sensing and imaging -- and an exhibition showcasing 382 ...
Breaking Biology Technology:Biotechnology Manufacturer Nitto Avecia Expands Capacity to Meet Client Demand 2Pfenex Inc. Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters' Option to Purchase Additional Shares 2Phytomer introduces DOUCEUR INTEMPORELLE Restorative Shield Cream 2Phytomer introduces DOUCEUR INTEMPORELLE Restorative Shield Cream 3SPIE DSS provides venue for collaboration vital to research, applications advances 2SPIE DSS provides venue for collaboration vital to research, applications advances 3SPIE DSS provides venue for collaboration vital to research, applications advances 4
... Technology, Inc. ("ACT"; OTC Bulletin Board: ACTC ... announced today that Gary Rabin, the company,s interim chairman ... BIO-Europe Spring 2011 Conference, March 14-16, at the Milano ... scheduled for Wednesday, March 16, at 10:15 a.m. CET, ...
... --Tianyin Pharmaceutical Co., Inc. (NYSE Amex: TPI ... medicine, modernized traditional Chinese medicine, branded generics and other ... Annual OC Growth Stock Conference from March 13 - ... California. Dr. James Jiayuan Tong, Chief Financial ...
... 2011 BioSpecifics Technologies Corp. (Nasdaq: BSTC ; ... products, today announced its financial results for the fourth quarter ... "2010 was an exciting year for the Company, but we ... to sales growth of XIAFLEX® in the U.S., as well ...
Cached Biology Technology:ACT Interim Chairman and CEO Gary Rabin to Present at BIO-Europe Spring 2011 Conference 2TPI Attends 23rd ROTH Annual OC Growth Stock Conference from March 13-16, 2011 2BioSpecifics Technologies Corp. Reports Fourth Quarter and Full Year 2010 Financial Results 2BioSpecifics Technologies Corp. Reports Fourth Quarter and Full Year 2010 Financial Results 3BioSpecifics Technologies Corp. Reports Fourth Quarter and Full Year 2010 Financial Results 4BioSpecifics Technologies Corp. Reports Fourth Quarter and Full Year 2010 Financial Results 5BioSpecifics Technologies Corp. Reports Fourth Quarter and Full Year 2010 Financial Results 6BioSpecifics Technologies Corp. Reports Fourth Quarter and Full Year 2010 Financial Results 7
(Date:4/2/2015)... , April 2, 2015 ... Q1 2015 attributed to somewhat higher than 125 MSEK. ... the year-end report 2014 that revenues for Q1 2015 ... the company reported for Q4 2014. The operating result ... be negative. The complete interim report will as previously ...
(Date:3/31/2015)... 2015   Guidepoint , a leading global research ... Pain Management TRACKER, part of the Guidepoint TRACKER ... the medical device and therapeutics markets. The Post-Surgical Pain ... volumes, market share, and adoption rates across three major ... surgery. The Post-Surgical Pain Management TRACKER will ...
(Date:3/24/2015)... 24, 2015   NexID Biometrics LLC, whose ... needs, today announced the beginning of shipments of version ... The company, based in Potsdam, N.Y. ... Connect:ID Expo, which began here today at the Walter ... 2.0 of its SDK boosts the accuracy rate range ...
Breaking Biology News(10 mins):Fingerprint Cards Revises Revenues for Q1 2015 2Guidepoint Launches Post-Surgical Pain Management TRACKER 2Guidepoint Launches Post-Surgical Pain Management TRACKER 3NexID Begins Shipments Of Version 2.0 Fake-Finger-Detection Solution 2
... This press relase is available in Spanish ... coloration of pickles, skin during fermentation may actually help ... a U.S. Department of Agriculture (USDA) study. ... when combined with tartrazine, a yellow food-coloring agent used ...
... of a portion of the tuberculosis genome that responds to ... Tiwari to zero in on a network of genes that ... cause tuberculosis (TB), Mycobacterium tuberculosis, can transition into a dormant ... system. A new report from Igoshin and Tiwari in this ...
... 2010 Science in Society Journalism Awards, sponsored by the National ... In the Book category, Susan Cohen and Christine Cosgrove for ... Medical Industry,s Quest to Manipulate Height" (Tarcher/Penguin). In ... Associated Press and the New York Times. Martha Mendoza and ...
Cached Biology News:Pickle spoilage bacteria may help environment 2Study finds possible 'persistence' switch for tuberculosis 2Study finds possible 'persistence' switch for tuberculosis 3Science in Society Journalism Award winners announced 2Science in Society Journalism Award winners announced 3
...
... J. Davison and Richard ... Contents include: information on ... paramyxoviruses, influenza and immunodeficiency ... analysis of viral NA ...
Performance, mycoplasma, virus, and endotoxin tested. Collected from calves 14 days old or less...
Healthy animals 10-32 weeks of age, mixed gender and breed; collected on wet ice following USDA guidelines, using Alsevers solution at 1:2 dilution...
Biology Products: